MilliporeSigma Unveils ColorWheel Flow Cytometry Portfolio
MilliporeSigma’s new ColorWheel flow cytometry portfolio is designed to create antibodies and dyes analogous to a primary conjugated antibody.
MilliporeSigma announced the launch of its new ColorWheel flow cytometry portfolio on Nov. 16, 2021. The ColorWheel uses technology optimized for flow cytometry that allows users to select antibodies and dyes for assembly in any desired combination, resulting in an output of mix-and-match antibodies and dyes analogous to a primary conjugated antibody.
According to a company press release, multiplexing in flow cytometry can be difficult because researchers must consider instrument configuration, antigen expression and dye brightness balance, and antibody–dye combination availability. In this regard, the ColorWheel is designed to overcome these constraints by making it easier to build a new multiplex assay for samples with varying expression levels of antigen.
According to the press release, the ColorWheel:
- Has the flexibility to pair any antibody with any dye in a ready-to-use, convenient format
- Can be used in five minutes of hands-on time, minimizing necessary time and effort
- Uses a preservative-free presentation that promotes sustainability and wider sample type compatibility
- Delivers a lyophilized product, enhancing stability and allowing for ambient shipping.
Source: MilliporeSigma
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
